Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Table 5 Optimal cut-off values of lipid fluctuation for DFS

Lipid fluctuation^a	N (%)	Number of events	DFS (months), median and range	P value
Cholesterol (mmol/L)				0.20
< 0.14	16 (13.7)	8	80.43 (0.70-81.17)
≥ 0.14	101 (86.3)	63	28.97 (1.70-85.47)
Triglyceride (mmol/L)				0.020
< 0.25	61 (52.1)	31	47.40 (3.23–85.47)
≥ 0.25	56 (47.9)	40	26.28 (0.70–83.80)
HDL-C (mmol/L)				0.0069
< 0.32	72 (61.5)	38	49.70 (1.70-85.47)
≥ 0.32	45 (38.5)	33	19.17 (0.70-82.13)
LDL-C (mmol/L)				0.17
< 1.15	91 (77.8)	59	29.73 (0.70-82.33)
≥ 1.15	26 (22.2)	12	Unmature (3.23–85.47)
ApoA-I (g/L)				0.018
< 0.50	90 (76.9)	50	42.17 (0.70-85.47)
≥ 0.50	27 (23.1)	21	18.93 (4.60–77.60)
ApoB (g/L)				0.14
< 0.14	72 (61.5)	48	27.32 (0.70-82.07)
≥ 0.14	45 (38.5)	23	53.00 (2.37–85.47)

Data are mean ± standard deviations
Abbreviations: DFS disease free survival, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA-I apolipoprotein A-I, ApoB apolipoprotein B
^aDifference = lipids post-chemotherapy –lipids pre-chemotherapy

ISSN: 1476-511X